

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hastings et al.

Application Serial No.: 09/037,460


Art Unit: 1646

Filed: March 10, 1998

Examiner: Saoud, C.

For: Human Vascular IBP-Like Growth Factor

Attorney Docket No.: PF147D



#22
Sg
11/2/00
L

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to reference AH listed on the attached form PT/SB/08A. A copy of reference AH is enclosed.

Identification of the listed reference is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97, because this Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, a fee of \$240.00 is believed to be due. Accordingly, please charge the required fee or any other fee determined necessary, to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: Oct 25, 2000


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5772

Enclosures
MW/CB/lcc